Therefore, MSC potently inhibit Th17 differentiation from naïve and memory T-cell precursors and inhibit naturally-occurring Th17 cells from a site of inflammation.
Summary
Mesenchymal stem cells (MSC) inhibit T-cell activation and proliferation but their effects on individual T-effector pathways and on memory compared to naïve T-cells remain unclear. MSC influences on differentiation of naïve and memory CD4 + T-cells toward the Th17 phenotype were examined. CD4 + T-cells, activated under Th17-skewing conditions, exhibited reduced CD25 and IL-17A expression following MSC co-culture. Inhibition of IL-17A production persisted upon re-stimulation in the absence of MSC. The effects were attenuated when cell-cell contact was prevented.
Th17 cultures from highly-purified naïve-and memory-phenotype responders were similarly inhibited. Th17 inhibition by MSC was reversed by indomethacin and a selective COX-2 inhibitor. Medium from MSC/Th17 co-cultures contained increased levels of prostaglandin E2 (PGE2) and potently suppressed new Th17 cultures. MSC inhibition of Th17 differentiation was reversed by a selective EP4 antagonist and was mimicked by synthetic PGE2 and a selective EP4 agonist. Activation-induced IL-17A
secretion by naturally-occurring, effector-memory Th17 cells from a urinary
Introduction
The immune suppressive properties of MSC have garnered increasing attention over the past decade and constitute a central mechanism for MSC therapeutic benefits [1] [2] [3] [4] .
Specific modulatory effects of MSC from human and experimental animal sources have been described for the differentiation, activation, proliferation and effector functions of multiple innate and adaptive immune cells [5] [6] [7] [8] [9] [10] [11] . Among these, MSCmediated inhibition of primary T-cell activation and proliferation, suppression of DC maturation and promotion of regulatory phenotypes in monocyte/macrophages and Tcells have been most extensively characterised [7-9, 11, 12] .
In keeping with a paracrine or "trophic" model of MSC function in vivo [13] , various MSC-produced soluble mediators have been implicated in these immunomodulatory effects including IL-10, IL-6, HGF, TGFβ, chemokine ligand-2 (CCL2), HLA-G, NO, tumor necrosis factor-inducible gene 6 protein (TSG-6), prostaglandin E2 (PGE2) and kyneurenine [1, 2, 7, 9, 12, [14] [15] [16] . For some such mediators, expression by MSC may be dependent on pre-exposure to exogenous factors (e.g. IFNγ, TNF) or on contactdependent MSC/target cell cross-talk [2, 7, [16] [17] [18] [19] . The potential for harnessing MSC immunomodulatory properties has been highlighted by results in pre-clinical models of autoimmunity, allotransplantation, sepsis and acute ischemic injury [1, 4, 7, 14, 15] as well as by outcomes from clinical trials in inflammatory bowel disease, graftversus-host disease and myocardial infarction [1, 20] .
T-cells represent the primary effector cells for common autoimmune diseases and for rejection of transplanted organs and tissues [21] . Furthermore, activated memory Tcells have been implicated in non-antigen-specific forms of tissue injury such as ischemia-reperfusion [22, 23] . In addition to the investigation of mechanisms underlying MSC inhibition of T-cell activation, attention has also been directed toward their influence on specific T-cell effector phenotypes including CD8 + CTL and the Th1, Th2 and T-reg sub-types of CD4 + T-cells which may be more or less prominent in individual immune-mediated diseases [12, [24] [25] [26] . In vitro and in vivo experimental evidence would suggest that MSC are consistently suppressive of CTLand Th1-mediated immune responses while being less inhibitory toward Th2-type responses and actively promoting T-reg survival and expansion [9, 12, 27] . Less well understood for each of these subsets are the relative effects of MSC on naïve T-cells undergoing primary activation compared to previously activated, or memoryphenotype, T-cells.
The recent description of an additional CD4 + T-cell subset, termed Th17 cells, has added further complexity to our understanding of cellular adaptive immunity [28] . The Th17 effector phenotype is characterised by synthesis of a signature cytokine, IL-17A, in addition to IL-17F, IL-21, IL-22 and CCL20 [29] . Th17 cells have been shown to mediate localised tissue inflammation as a defence against infection but also play a pathogenic role in immunological diseases including rheumatoid arthritis, multiple sclerosis, Crohn's disease, psoriasis and glomerulonephritis [28, 30, 31] . Th17 differentiation, activation and expansion are now known to be promoted by the combined influences of several cytokines including IL-6, TGFβ1, IL-1, IL-21 and IL-23 [29] . To date, only a small number of studies have addressed the interaction between MSC and Th17 cells with evidence emerging for both suppressive and augmenting effects of MSC on this Th cell differentiation pathway [9, 14, [32] [33] [34] ].
In the current study, we extend the understanding of MSC-mediated inhibition of Th17 cells and provide evidence for potential therapeutic benefits of MSC therapies in suppressing both de novo and ongoing pathogenic Th17 immune responses.
Results

Dose-and contact-dependent inhibition of Th17 differentiation by MSC: B6 MSC
were co-cultured with CD4 + T-cells during primary activation under Th17-skewing conditions at ratios of 1:2000-1:20. In these cultures, the day-4 concentration of IL-17A and the surface expression level of CD25 by CD4+ T-cells were reduced in dosedependent fashion ( Figure 1A, 1B) . When re-stimulation of equal numbers of CD4 + cells retrieved from the cultures was carried out using anti-CD3/anti-CD28 beads, IL17A production was lower for cells generated in the presence of MSC ( Figure 1C) .
In multiple experiments, inhibition was consistently observed at MSC:T-cell ratios as low as 1:400. Although IFNγ has been reported to be necessary for triggering of maximal T-cell inhibitory effects of MSC under some conditions [17, 19] , omission of anti-IFNγ from the co-cultures was not associated with more potent Th17 suppression (Supplementary Figure S2) . The inhibitory effect of MSC on Th17 activation was not strain-specific being demonstrable for MSC from BALB/c and DBA mice (Supplemental Figure S3A, S3B) . Furthermore, B6 MSC inhibited IL-17A
production by BALB/c CD4 + T-cells undergoing primary Th17 induction (Supplemental Figure S3C) .
A requirement for initial cell-cell contact was examined using Transwell® cultures in which CD4 + T-cells undergoing primary Th17 induction in the lower compartment were separated from MSC in the upper compartment. In these experiments, modest reduction of CD25 surface level on CD4 + T-cells was observed at several MSC:T-cell ratios but reduction in IL-17A production following re-stimulation occurred only at the highest MSC:T-cell ratio (Figure 2A,2B) . Consistently, comparable degrees of Th17 inhibition in cultures lacking direct T-cell/MSC contact required ≥10-fold greater MSC numbers than direct contact co-cultures. Figure 3A ) and were separately activated under Th17-skewing conditions. For both responder populations, co-culture with low numbers of MSC (MSC:T-cell ratio 1:400) was associated with inhibition of CD25 up-regulation ( Figure 3B ) and IL-17A production upon restimulation ( Figure 3C ). Qualitatively similar results were observed in a total of 5 similar experiments with median proportionate inhibition of IL-17A production following re-stimulation of 26% (range 13-66%) for memory-phenotype responders and 66% (range 33-80%) for naïve-phenotype responders. As shown in Figure 4 , coculture of both naïve-and memory-phenotype CD4 + T-cells with a low ratio of MSC was associated with a moderate anti-proliferative effect under Th17-skewing conditions using CFSE labelling (4A) and a reduced proportion of IL-17A + cells
Inhibition of Th17 induction by MSC occurs with both naïve-and memory-phenotype
within each generation of cell division using intra-cellular staining for IL-17A (4B and 4C). It was concluded that the presence of low numbers of MSC during a Th17-biased activation culture of either naïve or memory CD4 + T-cells resulted in separate effects on T-cell proliferation and on induction of high-level IL-17A production.
In additional experiments the specificity and direct nature of MSC suppression of Th17 differentiation was demonstrated. Inhibition of IL-17A secretion upon restimulation of Th17-skewed naïve-and memory-phenotype CD4 + cells was not apparent following co-culture with primary fibroblasts (Supplemental Figure S4A) .
The possibility that monocyte/macrophages or DCs were responsible for indirectly mediating MSC suppressive effects on T-cell responders was eliminated by experiments in which primary CD4 + T-cell/MSC co-cultures were initiated with anti-CD3/anti-CD28-coated beads rather than splenic APCs. In this case, the Th-17-suppressive effect of MSC for both naïve and memory CD4+ T-cells persisted (Supplemental Figure S4B) . In the current study we have addressed such issues with a focus on the Th17 differentiation pathway -a pro-inflammatory Th cell effector phenotype with pathogenic potential in a range of immune-mediated diseases [28, 29] . We demonstrate that low numbers of MSC are capable of suppressing de novo Th17 differentiation through a mechanism that is initiated most potently by MSC/T-cell contact but is subsequently mediated by PGE2 acting via the EP4 receptor. In contrast to other reported T-cell inhibitory phenomena [17, 19] , we find that IFNγ- antigen-specific Th17 cells in rat EAE and autoimmune myasthenia gravis and in established autoimmune diabetes mellitus in NOD mice [32, 33] . Interestingly, however, evidence for enhancement of Th17 differentiation and IL-17A production by MSC and fibroblasts has also been presented in a small number of studies [34, 35] .
MSC suppressive effect on primary
The reported results suggested that MSC production of IL-6 as well as stimulation of IL-1 and/or IL-23 secretion by APCs were responsible for the observations [34, 35] . reversed MSC-mediated suppression of Th17 differentiation from human naïve, cordblood CD4 + T-cells as well as IL-17A production by Th17 clones [9] . By utilizing FACS to re-purify MSC, we convincingly demonstrate significant up-regulation of reported that PGE2 enhanced expansion of Th17 cells in vitro and in vivo through PGE2-EP4 signalling. This effect was mediated, however, indirectly through IL-23
and, in this study, PGE2 was also shown to dose-dependently suppress Th17 differentiation from naïve CD4 + T-cells in an APC-free culture system [38] .
Nonetheless, enhancement of Th17-mediated immune responses by PGE2/EP4 signalling has also been described in other experimental settings [39, 40] . Given the pleiotropic effects and diverse cellular targets of PGE2 in vivo, it appears unlikely that the inhibitory effects of MSC on Th17 cell differentiation and activation can be selectively reproduced in an active disease setting by administration of COX-2 inhibitor or EP4 agonist. Rather, the combined effects of PGE2 and other MSCassociated mediators may be necessary to additionally regulate the production of Th17-promoting factors by ancillary cell populations such as dendritic cells and monocyte/macrophages [7, 12] .
In conclusion, this study provides novel evidence that MSC-derived PGE2 is highly induced in Th17-MSC co-cultures and mediates a potent suppressive effect on primary and secondary Th17 induction via the EP4 receptor. We propose that further characterisation of the interactions between Th17 cells and MSC, including the nature of the contact-dependent signal responsible for COX-2 up-regulation, will identify additional opportunities for manipulation of the Th17 differentiation program.
Furthermore, suppression of IL-17A production by effector-memory Th17 cells derived from a site of "sterile inflammation" indicates the potential for MSC to ameliorate tissue damage associated with maladaptive acute or chronic Th17 activation if delivered in the correct context. 
Materials and Methods
Experimental animals and reagents:
MSC isolation and characterisation:
Mouse MSC were isolated from bone marrow according to the method described by Peister et al [41] . Tri-lineage differentiation capacity was determined using standard chondrogenic, adipogenic and osteogenic differentiation assays (Supplemental Figure S1 ) [18] . All experiments were carried out with passage 5 to 8 MSC grown to 80% confluence in T75 tissue culture flasks Transwell® 96 well permeable supports (Sigma-Aldrich) at 1x10 6 /ml and 2x10 6 /ml respectively with 1μg/ml anti-CD3ε, 5μg/ml anti-IFNγ, 4μg/ml anti-IL-4, 5ng/ml TGF-β1 and 25ng/ml IL-6. In some experiments, CD4 + T-cells were cultured at Relative quantification was performed using the comparative C T method with results expressed as fold difference relative to the MSC-alone sample.
Unilateral ureteral obstruction (UUO) in mice:
UUO with preparation of cell suspensions by collagenase/DNase digestion was conducted as previously described [22, 43] (see also Supplemental Methods). Leukocyte-enriched fractions were prepared from kidney cell suspensions by positive magnetic selection using anti-CD45 microbeads (Miltenyi Biotec). CD45-positive cells (2x10 6 /ml) were cultured for 24-48 hours in 96-well round-bottom plates with 0.01μg/ml anti-CD3ε with graded numbers of MSC and other reagents as described for individual experiments.
Statistical Analysis: Individual experiments were carried out between 2 and 7 times to ensure reproducibility. For culture experiments, individual conditions were generated in replicates of 3-6 and assayed separately. Results were expressed throughout as mean + SD and differences between conditions tested statistically by two-tailed, unpaired Student's t-test. Significance was assigned at p < 0.05. 
